

Resource Summary Report

Generated by [dkNET](#) on Aug 25, 2026

Phoenix-Eco

RRID:CVCL_H717

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3214, RRID:CVCL_H717

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_H717

Proper Citation: ATCC Cat# CRL-3214, RRID:CVCL_H717

Description: Cell line Phoenix-Eco is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Comments: Characteristics: Capable of delivering genes to dividing murine or rat cells., Group: Retrovirus packaging cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: Phoenix-Eco

Synonyms: Phoenix-ECO, Phoenix Eco, PhoenixEco, Phoenix-E, Phoenix E

Cross References: ATCC:CRL-3214, ATCC:SD-3444, Wikidata:Q54947368

ID: CVCL_H717

Vendor: ATCC

Catalog Number: CRL-3214

Hierarchy: cvcl_1926

Record Creation Time: 20250130T072642+0000

Record Last Update: 20260816T001441+0000

Ratings and Alerts

No rating or validation information has been found for Phoenix-Eco.

Warning: Discontinued: ATCC; SD-3444

Characteristics: Capable of delivering genes to dividing murine or rat cells., Group: Retrovirus packaging cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 61 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Powers J, et al. (2026) eIF4G2-dependent translation restrains pancreatic cancer progression. bioRxiv : the preprint server for biology.

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine, 7(7), 102885.

Wang Y, et al. (2026) Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC class I-deficient solid tumors. Cell reports, 45(3), 117035.

Bajbouj K, et al. (2026) Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors. Cancer immunology research, 14(4), 559.

Terraneo F, et al. (2026) The glycine-arginine-rich motif of 53BP1 modulates RNA interactions necessary for its liquid-liquid phase separation during DNA Damage Response. bioRxiv : the preprint server for biology.

López-Hernández L, et al. (2026) BCLAF1 links RNA splicing to ATF4-dependent metabolic adaptation in acute myeloid leukemia. bioRxiv : the preprint server for biology.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Clubb JD, et al. (2026) Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. Cancer research, 86(15), 3781.

Zuo Y, et al. (2025) IL-36? armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity. Cancer cell.

- Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. *Cell reports*, 44(10), 116404.
- Indeglia A, et al. (2025) Targeted citrullination enables p53 binding to non-canonical sites. *Molecular cell*, 85(19), 3588.
- Li Q, et al. (2025) Long noncoding RNA-dependent control of Myc transcriptional bursting. *Cell reports*, 44(10), 116439.
- Buri MC, et al. (2025) Natural Killer Cell-Mediated Cytotoxicity Shapes the Clonal Evolution of B-cell Leukemia. *Cancer immunology research*, 13(3), 430.
- Doggett K, et al. (2025) Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers. *EMBO reports*, 26(15), 3937.
- Zhong W, et al. (2025) Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. *Nature cancer*, 6(7), 1157.
- Xu J, et al. (2025) BCOR and ZC3H12A suppress a core stemness program in exhausted CD8⁺ T cells. *The Journal of experimental medicine*, 222(8).
- Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. *Cancer cell*, 43(1), 49.
- Nam JS, et al. (2025) An Iron-regulated Signalling Pathway Controls Adipose Browning and Cancer Cachexia. *bioRxiv : the preprint server for biology*.
- Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. *The Journal of experimental medicine*, 221(5).